Preview

Рецепт

Расширенный поиск

Магнийсодержащие лекарственные препараты: от клинической фармакологии до фармацевтической помощи (2-я часть)

https://doi.org/10.34883/PI.2021.24.2.005

Полный текст:

Аннотация

Магнийсодержащие лекарственные препараты могут применяться перорально, внутримышечно или внутривенно. Терапия магнийсодержащими препаратами должна осуществляться до нормализации концентрации магния, а курс терапии должен составлять не менее одного месяца. В статье приводятся рекомендации по применению магнийсодержащих препаратов в различных популяционных группах. Магнийсодержащие препараты можно применять во время беременности с учетом оценки пользы/риска для матери и плода. Особое внимание уделено сравнительной оценке эффективности соединений магния в клинической практике по результатам анализа статей базы данных медицинских и биологических публикаций PubMed. Установлено, что в Республике Беларусь зарегистрировано 19 магнийсодержащих препаратов, для которых рассчитано содержание свободного магния в каждой дозированной единице лекарственной формы. Разработан алгоритм оказания фармацевтическим работником грамотной фармацевтической помощи (в т. ч. фармацевтического консультирования) посетителю, обратившемуся в аптеку с вопросом о приобретении магнийсодержащих препаратов.

Об авторе

А. А. Кирилюк
РУП «БЕЛФАРМАЦИЯ»
Беларусь


Список литературы

1. Whittlesea C., Hodson K. (2019) Clinical pharmacy and therapeutics. UК: Elsevier.

2. DiPiro J., Talbert R., Yee G., Matzke G., Wells B., Michael Posey L. (2016) Pharmacotherapy: a pathophysiologic approach. USA: McGraw-Hill Education.

3. Chisholm-Burns M., Schwinghammer T., Wells B., Malone P., DiPiro J., Kolesar J., Katz M., Matthias K. (2016) Pharmacotherapy Principles & Practice. USA: McGraw-Hill Education.

4. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. USA: National Academy Press.

5. Lerchenfeldt S., Rosenfeld G. (2020) BRS Pharmacology. USA: Wolter Kluwer.

6. Katzung B.G. (2018) Basic & Clinical Pharmacology. USA: McGraw-Hill Education.

7. Weiner C.P., Mason C. (2019) Drugs for pregnant and lactating women. USA: Elsevier Inc.

8. Reyestry UP Tsentr ekspertiz i ispytaniy v zdravookhranenii [Electronic resource]. Access mode: http://www.rceth.by. Date of access: 12.10.2020.

9. Classen H.G. (2004) Magnesium orotate – experimental and clinical evidence. Rom J Intern Med., no 42 (3), pp. 491–501.

10. Gromova O.A., Torshin I.Yu., Kalacheva A.G., Fedotova L.E., Rudakov K.V. (2016) Molekulyarnye mekhanizmy deistviya pidolata magniya i ego neirotropnye effekty [Molecular mechanisms of pidolate magnesium action and its neurotropic effects]. Zh Nevrol Psikhiatr Im S.S. Korsakova, no 116(12), pp. 96–103.

11. Kass L. (2017) Magnesium: supplementation, absorption and effect on blood pressure and exercise [University of Exeter as a thesis for the degree of PhD]. Sport and Health Sciences.

12. Okusanya B.O., Oladapo O.T., Long Q., Lumbiganon P., Carroli G., Qureshi Z., Duley L., Souza J.P., Gülmezoglu A.M. (2016) Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG, no 123(3), pp. 356–366.

13. PubMed. National Center for Biotechnology Information [Electronic resource]. Mode of access: https://pubmed.ncbi.nlm.nih.gov. Data of access: 28.06.2020.

14. Find Drugs & Conditions. Drugs.com [Electronic resource]. Mode of access: https://www.drugs.com. Data of access: 28.08.2020.

15. Engen D.J., McAllister S.J., Whipple M.O., Cha S.S., Dion L.J., Vincent A., Bauer B.A., Wahner-Roedler D.L. (2015) Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study. J Integr Med., no 13(5), pp. 306–313.

16. Ajilore B.S., Alli A.A., Oluwadairo T.O. (2018) Effects of magnesium chloride on in vitro cholinesterase and ATPase poisoning by organophosphate (chlorpyrifos). Pharmacol Res Perspect, no 6(3), pp. e00401.

17. Alarcón P.O., Sossa K., Contreras D., Urrutia H., Nocker A. (2014) Antimicrobial properties of magnesium chloride at low pH in the presence of anionic bases. Magnes Res., no 27(2), pp. 57–68.

18. Greiner J., Diezel W. (1990) Entzündungshemmende Wirkung von Magnesium-Ionen bei der Kontaktekzem-Reaktion [Inflammation-inhibiting effect of magnesium ions in contact eczema reactions]. Hautarzt., no 41(11), pp. 602–605.

19. Mizrahi B., Shapira L., Domb A.J., Houri-Haddad Y. (2006) Citrus oil and MgCl2 as antibacterial and anti-inflammatory agents. J Periodontol., no 77(6), pp. 963–968.

20. Hankins J.S., Wynn L.W., Brugnara C., Hillery C.A., Li C.S., Wang W.C. (2008) Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol., no 140(1), pp. 80–85.

21. Than N.N., Soe H.H.K., Palaniappan S.K., Abas A.B. (2017) Magnesium for treating sickle cell disease. Cochrane Database Syst Rev., no 4(4), pp. CD011358.

22. De Franceschi L., Bachir D., Galacteros F., Tchernia G., Cynober T., Neuberg D., Beuzard Y., Brugnara C. (2000) Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol., no 108(2), pp. 284–289.

23. Destro G. (1990) Effetti del magnesio pidolato sull’emodinamica cardiovascolare [Effects of magnesium pidolate on cardiovascular hemodynamics]. Cardiologia, no 35(12), pp. 1027–1032.

24. De Falco C.N., Darrieux F.C., Grupi C., Sacilotto L., Pisani C.F., Lara S., Ramires J.A., Sosa E., Wu T.C., Hachul D., Scanavacca M. (2014) Late outcome of a randomized study on oral magnesium for premature complexes. Arq Bras Cardiol., no 103(6), pp. 468–475.

25. Teste J.F., Decelle T., Henrotte J.G. (1995) Propriétés psychopharmacologiques de trois sels de magnésium: pidolate, lactate et aspartate [Psychopharmacological properties of three magnesium salts: pidolate, lactate and aspartate]. Ann Pharm Fr., no 53(4), pp. 176–183.

26. Spasov A.A., Petrov V.I., Iezhitsa I.N., Kravchenko M.S., Kharitonova M.V., Ozerov A.A. (2010) Comparative study of magnesium salts bioavailability in rats fed the magnesium-deficient diet. Vestn Ross Akad Med Nauk., no 2, pp. 29–37.

27. Pascoal A.C.F., Katz L., Pinto M.H., Santos C.A., Braga L.C.O., Maia S.B., Amorim M.M.R. (2019) Serum magnesium levels during magnesium sulfate infusion at 1gram/hour versus 2grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial. Medicine (Baltimore), no 98(32), pp. e16779.

28. Mebazaa M.S., Ouerghi S., Frikha N., Moncer K., Mestiri T., James M.F., Ben Ammar M.S. (2011) Is magnesium sulfate by the intrathecal route efficient and safe? Ann Fr Anesth Reanim., no 30(1), pp. 47–50.

29. Shepherd E., Salam R.A., Manhas D., Synnes A., Middleton P., Makrides M., Crowther C.A. (2019) Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. PLoS Med., no 16(12), pp. e1002988.

30. Malek-Mellouli M., Atef Y., Ben Amara F., Nasr M., Khaled N., Bouchnack M., Maghrebi H., Reziga H. (2012) Sulfate de magnésium au cours de la préeclampsie sévère: Innocuité d’utilisation? [Safety of Magnesium sulfate in severe preeclampsia]. Tunis Med., no 90(7), pp. 552–556.

31. Zhang Q., Zhou P.H., Zhou X.L., Zhang D.L., Gu Q., Zhang S.J., Zhang J., Zhang J.S., Qian Z.Y. (2018) Effect of magnesium gluconate administration on lipid metabolism, antioxidative status, and related gene expression in rats fed a high-fat diet. Magnes Res., no 31(4), pp. 117–130.

32. Li S., Tian H. (1997) Oral low-dose magnesium gluconate preventing pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi, no 32(10), pp. 613–615.

33. Mak I.T., Komarov A.M., Kramer J.H., Weglicki W.B. (2000) Protective mechanisms of Mg-gluconate against oxidative endothelial cytotoxicity. Cell Mol Biol (Noisy-le-grand), no 46(8), pp. 1337–1344.

34. Schutten J.C., Joris P.J., Mensink R.P., Danel R.M., Goorman F., Heiner-Fokkema M.R., Weersma R.K., Keyzer C.A., de Borst M.H., Bakker S.J.L. (2019) Effects of magnesium citrate, magnesium oxide and magnesium sulfate supplementation on arterial stiffness in healthy overweight individuals: a study protocol for a randomized controlled trial. Trials, no 20(1), p. 295.

35. Roffe C., Sills S., Crome P., Jones P. (2002) Randomised, cross-over, placebo controlled trial of magnesium citrate in the treatment of chronic persistent leg cramps. Med Sci Monit., no 8(5), pp. CR326-CR330.

36. Shechter M., Saad T., Shechter A., Koren-Morag N., Silver B.B., Matetzky S. (2012) Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects. Magnes Res., no 25(1), pp. 28–39.

37. Moradian S.T., Ghiasi M.S., Mohamadpour A., Siavash Y. (2017) Oral magnesium supplementation reduces the incidence of gastrointestinal complications following cardiac surgery: a randomized clinical trial. Magnes Res., no 30(1), pp. 28–34.

38. Wang F., Van Den Eeden S.K., Ackerson L.M., Salk S.E., Reince R.H., Elin R.J. (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache., no 43(6), pp. 601–610.

39. Yoshida H., Takahashi M., Honda M., Amayasu H., Ando M. (2019) Co-administration of magnesium oxide reduces the serum concentration of hydrophobic basic drugs in patients treated with antipsychotic drugs. Biol Pharm Bull., no 42(6), pp. 1025–1029.

40. Baker W.L., Kluger J., White C.M., Dale K.M., Silver B.B., Coleman C.I. (2009) Effect of magnesium L-lactate on blood pressure in patients with an implantable cardioverter defibrillator. Ann Pharmacother., no 43(4), pp. 569–576.

41. Navarrete-Cortes A., Ble-Castillo J.L., Guerrero-Romero F., Cordova-Uscanga R., Juárez-Rojop I.E., Aguilar-Mariscal H., Tovilla-Zarate C.A., Lopez- Guevara Mdel R. (2014) No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia. Magnes Res., no 27(2), pp. 48–56.

42. Stepura O.B., Martynow A.I. (2009) Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol., no 134(1), pp. 145–147.

43. Wells B., DiPiro J., Schwinghammer T., DiPiro C. (2015) Pharmacotherapy Handbook, USA: McGraw-Hill Education.

44. Ross W.R., Preedy V.R., Sherma Z. (Eds.) (2013) Magnesium in human health and disease, USA: Springer Science + Business Media, Humana Press.

45. Papadakis M., McPhee S., Rabow M. (2019) CURRENT Medical Diagnosis & Treatment. USA: McGraw-Hill Education.

46. Vdovichenko V.P. (2014) Farmakologiya i farmakoterapiya: Posobiye dlya vrachey [Pharmacology and pharmacotherapy: A manual for doctors]. Minsk: Donarit. (in Russian)

47. Susan M. Ford (2014) Clinical pharmacology. USA: Wolters Kluwer.

48. Wecker L., Taylor D.A., Theobald R.J.Jr. (2019) Brody’s Human Pharmacology: Mechanism-based therapeutics. USA: Elsevier Inc., 2323 p.

49. Spasov A.A., Ozerov A.A., Iezhitsa I.N., Kharitonova M.V., Kravchenko M.S., Zheltova A.A. (2011) Correction of furosemide-induced magnesium deficiency with different stereoisomers of organic magnesium salts: a comparative study. Bull Exp Biol Med., no 151(3), pp. 333–335.


Для цитирования:


Кирилюк А.А. Магнийсодержащие лекарственные препараты: от клинической фармакологии до фармацевтической помощи (2-я часть). Рецепт. 2021;(2):226-240. https://doi.org/10.34883/PI.2021.24.2.005

For citation:


Kirilyuk .A. Magnesium-Containing Medicines: from Clinical Pharmacology to Pharmaceutical Assistance (Part 2). Recipe. 2021;(2):226-240. (In Russ.) https://doi.org/10.34883/PI.2021.24.2.005

Просмотров: 20


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)